

INTRODUCTION

- High-Sensitivity C-Reactive Protein and Cardiovascular Disease I. Young and N. Rifai 201

EDITORIALS

- Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death: Just Another Brick in the Wall? P.O. Collinson (see article on page 265) 203
- Inhibition of Endothelial Nitric Oxide Synthase by C-Reactive Protein: Clinical Relevance I. Jialal, S. Verma, and S. Devaraj (see article on page 274) 206

REFLECTION

- C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease P.M. Ridker 209

PERSPECTIVE

- Is hsCRP Back on Board? Implications from the JUPITER Trial W. Koenig 216

MINI-REVIEW

- The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines S. Mora, K. Musunuru, and R.S. Blumenthal 219

REVIEWS

- The Evolving Role of C-Reactive Protein in Atherothrombosis S. Devaraj, U. Singh, and I. Jialal 229
- C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target? A.D. Hingorani, T. Shah, J.P. Casas, S.E. Humphries, and P.J. Talmud 239
- Impact of Genetic and Environmental Factors on hsCRP Concentrations and Response to Therapeutic Agents J. Shen and J.M. Ordovas 256

ARTICLES

PROTEOMICS AND PROTEIN MARKERS

- Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death B.M. Scirica, C.P. Cannon, M.S. Sabatine, P. Jarolim, S. Sloane, N. Rifai, E. Braunwald, and D.A. Morrow, for the PROVE IT–TIMI 22 Investigators (see editorial on page 203) 265

- Adeno-Associated Virus–Mediated Human C-Reactive Protein Gene Delivery Causes Endothelial Dysfunction and Hypertension in Rats H. Guan, P. Wang, R. Hui, M.L. Edin, D.C. Zeldin, and D.W. Wang (see editorial on page 206) 274

- Oxidized LDL Receptor LOX-1 Binds to C-Reactive Protein and Mediates Its Vascular Effects Y. Fujita, A. Kakino, N. Nishimichi, S. Yamaguchi, Y. Sato, S. Machida, L. Cominacini, Y. Delneste, H. Matsuda, and T. Sawamura 285

- Lipopolysaccharide-Binding Protein: A New Biomarker for Infectious Endocarditis? T. Vollmer, C. Piper, K. Kleesiek, and J. Dreier 295

LIPIDS, LIPOPROTEINS, AND CARDIOVASCULAR RISK FACTORS

- Tracking of High-Sensitivity C-Reactive Protein after an Initially Elevated Concentration: The JUPITER Study R.J. Glynn, J.G. MacFadyen, and P.M. Ridker 305

- Seasonal and Sex Variation of High-Sensitivity C-Reactive Protein in Healthy Adults: A Longitudinal Study D.E. Chiriboga, Y. Ma, W. Li, E.J. Stanek III, J.R. Hébert, P.A. Merriam, E.S. Rawson, and I.S. Ockene 313

- Determinants of the Acute-Phase Protein C-Reactive Protein in Myocardial Infarction Survivors: The Role of Comorbidities and Environmental Factors R. Rückerl, A. Peters, N. Khuseynova, M. Andreani, W. Koenig, C. Meisinger, K. Dimakopoulou, J. Sunyer, T. Lanki, F. Nyberg, and A. Schneider 322

continued

ARTICLES, *continued*

- C-Reactive Protein Concentrations Are Very High and More Stable over Time Than the Traditional Vascular Risk Factors Total Cholesterol and Systolic Blood Pressure in an Australian Aboriginal Cohort T. Shemesh, K.G. Rowley, A.J. Jenkins, J.D. Best, and K. O’Dea 336
- Standardization of High-Sensitivity Immunoassays for Measurement of C-Reactive Protein; II: Two Approaches for Assessing Commutability of a Reference Material M.M. Kimberly, S.P. Caudill, H.W. Vesper, E.A. Monsell, W.G. Miller, R. Rej, N. Rifai, F. Dati, and G.L. Myers 342
- Relation of Genetic Variation in the Gene Coding for C-Reactive Protein with Its Plasma Protein Concentrations: Findings from the Women’s Health Initiative Observational Cohort C.C. Lee, N.Y. You, Y. Song, Y.-H. Hsu, J. Manson, L. Nathan, L. Tinker, and S. Liu 351

BRIEF COMMUNICATIONS

- C-Reactive Protein Stimulates Myeloperoxidase Release from Polymorphonuclear Cells and Monocytes: Implications for Acute Coronary Syndromes U. Singh, S. Devaraj, and I. Jialal 361
- Different Apparent Prognostic Value of hsCRP in Type 2 Diabetic and Nondiabetic Patients with Acute Coronary Syndromes L.M. Biasucci, G. Liuzzo, R. Della Bona, M. Leo, G. Biasillo, D.J. Angiolillo, A. Abbate, V. Rizzello, G. Niccoli, S. Giubilato, and F. Crea 365

CLINICAL CASE STUDY

- Myocardial Infarction in a 72-Year-Old Woman with Low LDL-C and Increased hsCRP: Implications for Statin Therapy P.M. Ridker 369

COMMENTARIES

- E.J. Schaefer 374
- E. Yang and C.M. Ballantyne 375

CITATION CLASSIC

- Simple and Reproducible ELISA for C-Reactive Protein R.P. Tracy 376

PREAMBLE


- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease NACB LMPG Committee Members: G.L. Myers (Chair), R.H. Christenson (Vice-Chair), M. Cushman, C.M. Ballantyne, G.R. Cooper, C.M. Pfeiffer, S.M. Grundy, D.R. Labarthe, D. Levy, N. Rifai, and P.W.F. Wilson 378

CLINICAL CHEMIST

- Lily Robinson and the Art of Secret Poisoning: Recollections 385

ACCENT®—CONTINUING EDUCATION CREDIT FOR READERS OF *CLINICAL CHEMISTRY*

For more information go to <http://apps.aacc.org.ccj/accent>



ON THE COVER The structure of C-reactive protein (CRP). Many individuals, but not all, consider this five-subunit member of the pentraxin protein family a useful marker for cardiovascular disease. CRP has recently gained increased medical interest because of the early termination of the JUPITER trial. This issue of *Clinical Chemistry* presents a broad range of articles covering multiple epidemiological, analytical, and clinical aspects of CRP (see page 201). Image reproduced with permission. © Keele University.

Color figures for Reviews sponsored by Department of Laboratory Medicine, Children’s Hospital Boston.